Search Results - neuroblastoma

7 Results

Sort By:

Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma

Abstract: Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed....

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Carol Thiele Galetto, Nan Li, Rosa Nguyen, Rosandra Kaplan

Keywords(s): CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotherapy, Medulloblastoma, Neuroblastoma, Retinoblastoma, Small-Cell Lung Cancers

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors

Abstract: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy. Investigators at the National...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li

Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma

Abstract: Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Dimiter Dimitrov

Keywords(s): ADC, ANTIBODY, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-2, GPC2, Immunotoxin, Neuroblastoma, Recombinant Immunotoxin, Rit

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers

Abstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Bryan Fleming

Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Chimeric Antigen Receptors to CD276 for Treating Cancer

Abstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. By...

Published: 4/8/2024 | Inventor(s): Crystal Mackall, Yongzhi Cui

Keywords(s): adoptive cell therapy, ANTIBODY, antigen-binding fragment, CAR, Neuroblastoma

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Therapeutic antibody-drug conjugates targeting CD56-positive cancers

Abstract: The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions. It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Yang Feng, Zhongyu Zhu, John Maris, Robyn Sussman

Keywords(s): ADC, GLYCOPROTEIN, MULTIPLE MYELOMA, Neuroblastoma, pyrrolobenzodiazepine, small-cell lung cancer

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Selections of Genes

The invention provides selections of genes expressed in a cancer cell that function to characterize such cancer, and methods of using the same for diagnosis and for targeting the therapy of selected cancers. In particular, methods are provided to classify cancers belonging to distinct diagnostic categories, which often present diagnostic dilemmas in...

Published: 7/25/2024 | Inventor(s): Javed Khan, Paul Meltzer

Keywords(s): AAXXXX, AXXXXX, Burkitt lymphoma; Burkitt's lymphoma, Burkitt's lymphoma, CA1AXX, CAXXXX, CXXXXX, Ewing's family of tumors, lymphoma, Neuroblastoma, Rhabdomyosarcoma 1, Rhabdomyosarcoma 2

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Oncology